Navigation Links
Egalet Announces Issuance of U.S. Patent
Date:7/24/2012

MALVERN, Pa., July 24, 2012 /PRNewswire/ -- Egalet Ltd., a privately held specialty pharmaceutical company focused on developing safe, effective and tamper-resistant medications, announced today a notice of allowance by the United States Patent and Trademark Office for its patent application Serial No. 2007/0042044 entitled: "Matrix Compositions for Controlled Delivery of Drug Substances." 

The patent relates to the Egalet® prolonged release technology.  The composition described by the patent family is utilized for all the Egalet® opioid products tested in clinical trials including the new improved tablet construction that has a very hard shell surrounding the erodible matrix containing the opioid. 

"This U.S. allowance adds to our patent portfolio that provides us with extensive coverage until 2033 for our novel, tamper-resistant technology," said Bob Radie, CEO and president.  "With the growing issue of abuse of pain medications, we believe we are well positioned to address the need for new safe treatments with Egalet's tamper-resistant opioids currently in development." 

Egalet has protected its inventions via extensive patenting and by know-how protection. The patent portfolio comprises both patent applications and issued patents that protect Egalet's different technologies as well as patent applications and issued patents that are specifically related to the product opportunities in the pipeline. This U.S. patent adds to the patents that have already been issued in Europe, Australia, New Zealand, India, Japan and Hong Kong.      

About Egalet Ltd.
Egalet Ltd. is a specialty pharmaceutical company using its patented technology to produce novel therapeutics on its own and with partners.  Based on the proprietary technology, Egalet is developing a pipeline of tamper-resistant opioids that are nearing pivotal testing.  In addition, Egalet has collaborations with pharmaceutical and biotechnology companies in the initial phase of clinical testing. 

Egalet has pioneered one of the world's first erosion-based delivery technologies to enable the controlled release of drugs through gradual erosion of a tablet.   In addition, the Egalet® technology, a novel, patented drug delivery platform, was designed to prevent easy extraction and to deter the abuse of medications via known routes of abuse, including chewing, snorting, and injecting.  The uniquely shaped, patient-friendly tablet consists of matrix and can add a shell or coat.  By altering the composition of the shell and matrix, a variety of extended-release formulations can be produced.  The technology offers a predictable and tailored pharmacokinetic profile, lacks a significant food effect and alcohol dose dumping, and can be used with a broad range of opioids and non-opioids.  Egalet has extensively filed patents to protect its inventions covering both the technology and product-specific patents.  Please visit www.egalet.com for more information.

Contact:
E. Blair Schoeb
Tel.: 908-277-0386
Email: blair@biotechcomm.com  


'/>"/>
SOURCE Egalet Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Egalet to Present at Life Sciences Europe Conference
2. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
3. Sancilio and Company Announces New Directors
4. Cerulean Announces First Patient Dosed in Phase 2 Study of CRLX101 in Ovarian Cancer
5. K-V Pharmaceutical Company Announces Additional Notification from NYSE Regarding Listing Criteria
6. Kraton Performance Polymers, Inc. Announces Second Quarter 2012 Earnings Release Conference Call and Webcast and 2012 Investor Day and Webcast
7. Rochester Medical Announces Third Quarter 2012 Earnings Conference Call Friday, July 27, 2012
8. Hologic Announces Pricing Of Financing In Connection With Acquisition Of Gen-Probe
9. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
10. China Health Resource Announces Go Global Initiative For New Product Introductions
11. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , February 8, 2016 ... new report published by Allied Market Research titled, ... Opportunities and Forecasts, 2014-2020", estimates the world synthetic ... Nucleotide synthesis and sequencing technology segment would continue ... and software tools segment, collectively, held around half ...
(Date:2/5/2016)... HILL, N.C. , Feb. 5, 2016  Despite ... has been slower than other industries to embrace Big ... come with utilization. On the medical side, organizations have ... improve everything from clinical trials to adherence. ... research from benchmarking firm Best Practices, LLC, Big Data ...
(Date:2/5/2016)... , Feb. 5, 2016  Syneron Medical ... aesthetic device company, announced today that William ... North America, is scheduled to participate in the ... Conference on February 11, 2016 in ... allow institutional investors to meet with the Mr. ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... ... be speaking on how healthcare companies can use newly released government data on ... of a population and intervene and capture the value they create to succeed ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... only four states in the U.S. require dental technicians to be certified or ... the dental industry, NADL created the “What’s In Your Mouth?” campaign to inform ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart ... employers and organizations with the tools and information to lower the costs, and ... cut the cost of providing employee healthcare benefits by as much as 22%:, ...
(Date:2/6/2016)... ... , ... US Sports Camps is proud to sponsor the Bay Area Disc ... non-profit leaders, ultimate organizations, and coaches from around the US. The theme for this ... Director of Youth and Education, describes this year YUCC as “an important conversation we ...
(Date:2/6/2016)... ... February 06, 2016 , ... Research ... treatment helps to reduce the frequency and level of relapse. , ... Healthy Identity and Purpose,” will explore the critical tasks of the recovery phase ...
Breaking Medicine News(10 mins):